Drug Discovery@nature.com 19 April 2013

Advertisement High Sensitivity Human Interferon Beta ELISA for disease sera Quantitates low or basal levels human interferon beta in serum, plasma, or tissue culture media with VeriKine-HS Human IFN beta Serum ELISA. This assay is suitable to measure trademarked IFN beta therapeutics in human serum. Learn More TABLE OF CONTENTS 19 April 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Structural & Molecular Biology FOCUS ON EPIGENETIC DYNAMICS This Focus explores emerging themes and the functional implications of epigenetic dynamics. Access the Focus for FREE at: www.nature.com/nsmb/focus/epigeneticdynamics This Focus is freely available thanks to support from Active Motif   News Top Zebrafish genome helps in hunt for treatments doi:10.1038/nature.2013.12821 Sequencing boosts researching on organisms increasingly useful for modelling human diseases. Full Text Gene patents in the dock doi:10.1038/496150a As US Supreme Court justices prepare to hear arguments in Myriad Genetics case, observers are debating the impact of the outcome on personal genomics. Full Text New yardstick could speed access to cancer drugs for surgery doi:10.1038/nm0413-383 The US Food and Drug Administration is moving toward issuing final guidance on the use of pathological complete response as a clinical trial endpoint for accelerated approval of drugs given ahead of breast cancer surgery. Full Text Underestimate of HIV reservoirs threatens purging approach doi:10.1038/nm0413-384 New findings indicate that HIV reservoirs may be much larger than previously thought, which might affect the development of therapeutic strategies aiming to eliminate the viral reservoir in HIV-infected individuals. Full Text Analysis Top RET, set, go doi:10.1038/scibx.2013.326 Just 15 months after Ret proto-oncogene fusions were first identified in 1%–2% of non–small cell lung cancer cases, early data from a Phase II trial of Exelixis Inc.'s Cometriq cabozantinib suggest that blocking the target could be effective in this patient population. Full Text Antibody–drug conjugates doi:10.1038/nrd3980 Antibody–drug conjugates (ADCs), which allow cytotoxic drugs to be selectively targeted to cancer cells, are attracting considerable interest. This article analyses the ADC pipeline, as well as trends in collaborations and deals related to ADC platforms. Full Text Research Highlights Top Metabolic disorders: Breaking the links between inflammation and diabetes doi:10.1038/nrd3988 Two papers identify approaches to inhibit the activity of the NF-κB pathway, which improved obesity-associated metabolic dysfunctions in mouse models Full Text Blood disorders: Epigenetically enhancing haemoglobin production doi:10.1038/nrd3998 Inhibition of lysine-specific demethylase 1 could be a promising approach for inducing γ-globin synthesis to treat β-globinopathies. Full Text Nanotechnology: Biological proteins knock nanoparticles off target doi:10.1038/nrd3983 Proteins present in biological serum can shield targeted nanoparticles from their intended target. Full Text Research & Reviews Top Adenosine receptors as drug targets — what are the challenges? doi:10.1038/nrd3955 Fredholm and colleagues provide an overview of the physiological and pathological functions of adenosine and consider the challenges in the development of compounds targeting adenosine receptors. Full Text Challenges and approaches for the development of safer immunomodulatory biologics doi:10.1038/nrd3974 This article discusses strategies to predict and mitigate adverse effects of immunomodulatory biologics, such as infections and cytokine release syndrome, and considers how they can be used to inform the development of safer drugs. Full Text Target identification and mechanism of action in chemical biology and drug discovery doi:10.1038/nchembio.1199 This review discusses approaches to target identification such as direct biochemical methods, genetic interactions and computational inference, and how they may be combined to characterize on-target and off-target effects and to understand mechanisms of action of small molecules. Full Text The why and how of phenotypic small-molecule screens doi:10.1038/nchembio.1206 This article discusses the basic principles underlying the design of phenotypic screens and proposes guidelines to facilitate the discovery of small molecules from them. Full Text Drug Discovery JOBS of the week Postdoctoral Positions in Structure Based Drug Design and Membrane Protein Structural Biology at Nanyang Technological University Nanyang Technological Univeristy, School of Biological Sciences Medicinal Chemist Team Leader Selvita Research Chemist In Hydrogels and Conducting Polymers University of Bordeaux Research Chemist Institute for Shock Physics/Applied Sciences Laboratory/Washington State University Research Chemist Econic Technologies More Science jobs from Drug Discovery EVENT Pediatric Drug Development 08.07.13 London - UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.